7.2 Pharmacotherapy for Mechanical Ventilation and ARDS

Board Certified Critical Care Pharmacist Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pathophysiology and Recognition of Critical Illness

1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness

2 Chapter 2: Medical Devices and Circulatory Support

2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care

3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management

3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation

4 Chapter 4: Vasoactive and Inotropic Therapy in Shock

4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock

5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)

5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness

6 Chapter 6: Cardiovascular Emergencies

6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias

7 Chapter 7: Pulmonary and Infectious Diseases in the ICU

7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU

8 Chapter 8: Neurocritical Care

8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury

9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies

9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy

10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition

10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral

11 Chapter 11: Quality, Safety, and Clinical Guidelines

11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions

12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine

12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management

13 Chapter 13: Treatment Planning and Care Coordination

13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education

7.2 Pharmacotherapy for Mechanical Ventilation and ARDS

Key Takeaways Explain This Topic AI

The cornerstone of ARDS management is lung-protective mechanical ventilation, targeting a low tidal volume (6 mL/kg predicted body weight) and plateau pressure < 30 cm H2O.

Neuromuscular blocking agents (NMBAs) like cisatracurium can be considered as an early, short-term (48 hours) infusion in severe ARDS (PaO2/FiO2 < 150) with significant ventilator dyssynchrony.

Systemic corticosteroids (e.g., dexamethasone) have been shown to increase ventilator-free days and reduce mortality in moderate-to-severe ARDS when given early.

Inhaled pulmonary vasodilators (e.g., inhaled nitric oxide, epoprostenol) provide transient improvements in oxygenation but do not improve survival; they are reserved as rescue therapy for refractory hypoxemia.

A conservative fluid management strategy (after initial resuscitation) reduces days on mechanical ventilation without increasing the risk of acute kidney injury.

Last updated: July 2026

Pharmacotherapy in ARDS

Acute Respiratory Distress Syndrome (ARDS) is an acute, diffuse, inflammatory lung injury leading to increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue. The Berlin Definition categorizes ARDS as mild, moderate, or severe based on the PaO2/FiO2 (P/F) ratio.

While non-pharmacologic interventions—specifically lung-protective mechanical ventilation and prone positioning—are the mainstays of reducing mortality, several pharmacologic therapies play a crucial adjunctive role in managing ARDS.

Mechanical Ventilation Basics in ARDS

Before discussing pharmacotherapy, it is vital to understand the goals of mechanical ventilation in ARDS, as medications are often used to facilitate these goals:

Low Tidal Volume Ventilation (LTVV): Target a tidal volume of 6 mL/kg of predicted body weight (PBW) . This prevents volutrauma to the remaining healthy alveoli.

Plateau Pressure: Maintain plateau pressure (the pressure applied to small airways and alveoli) ≤ 30 cm H2O to prevent barotrauma.

PEEP (Positive End-Expiratory Pressure): Moderate to high PEEP is used to recruit collapsed alveoli, prevent atelectrauma, and improve oxygenation.

Permissive Hypercapnia: Allowing PaCO2 to rise is often necessary to achieve low tidal volume goals, provided the pH remains acceptable (usually > 7.20-7.25).

Neuromuscular Blocking Agents (NMBAs)

In patients with moderate-to-severe ARDS, patient-ventilator dyssynchrony can lead to severe hypoxemia and further lung injury (patient self-inflicted lung injury). When deep sedation is insufficient to achieve synchrony and strict lung-protective ventilation, NMBAs may be employed.

Clinical Evidence

ACURASYS Trial (2010): Demonstrated a mortality benefit with early, 48-hour continuous infusion of cisatracurium in patients with severe ARDS (P/F < 150).

ROSE Trial (2019): Evaluated early continuous infusion of cisatracurium combined with heavy sedation versus lighter sedation without routine NMBAs. The trial found no mortality difference between the groups, challenging the routine use of NMBAs.

Current Recommendations

Routine continuous infusion of NMBAs is no longer widely recommended for all severe ARDS patients. However, short courses (≤ 48 hours) of continuous infusion (e.g., cisatracurium) are still utilized for specific indications: severe ventilator dyssynchrony despite deep sedation, facilitation of prone positioning, or persistently high plateau pressures. Patients receiving NMBAs require deep sedation (RASS -5) and regular monitoring (e.g., Train-of-Four) to ensure adequate paralysis and prevent awareness.

Corticosteroids in ARDS

The profound inflammatory cascade in ARDS provides a strong rationale for corticosteroid use. The goal is to attenuate the fibroproliferative phase and reduce systemic inflammation.

Clinical Evidence and Application

DEXA-ARDS Trial (2020): Evaluated the early use of intravenous dexamethasone (20 mg/day for 5 days, then 10 mg/day for 5 days) in moderate-to-severe ARDS. The trial demonstrated a significant increase in ventilator-free days and a reduction in 60-day mortality.

COVID-19 ARDS: The RECOVERY trial confirmed the mortality benefit of dexamethasone (6 mg daily for 10 days) in patients with COVID-19 requiring oxygen or mechanical ventilation.

Key Considerations

Corticosteroids are generally recommended for moderate-to-severe ARDS, provided there are no absolute contraindications (e.g., severe uncontrolled systemic fungal infection). Timing is critical; steroids should ideally be initiated early (within the first 14 days). Late initiation (after 14 days) in unresolving ARDS was historically associated with increased mortality.

Inhaled Pulmonary Vasodilators

Inhaled pulmonary vasodilators—such as inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO)—are used to selectively dilate pulmonary capillaries in well-ventilated lung regions. This improves ventilation-perfusion (V/Q) matching and acutely increases systemic oxygenation without causing systemic hypotension.

Role in Therapy

Despite providing rapid, often dramatic improvements in oxygenation, multiple randomized controlled trials have consistently shown that inhaled pulmonary vasodilators do not improve mortality or increase ventilator-free days in ARDS.

Therefore, they should not be used routinely. They are reserved exclusively as rescue therapy for life-threatening, refractory hypoxemia to buy time for other interventions (like prone positioning or ECMO) to work.

Adverse Effects and Rebound

iNO: Can cause methemoglobinemia and renal dysfunction. Requires gradual weaning to avoid severe rebound pulmonary hypertension and hypoxemia.

iEPO: Generally cheaper than iNO but can cause sticky residue in the ventilator circuit, potentially leading to obstruction.

Conservative Fluid Management

After the initial resuscitation phase for shock, ARDS patients often accumulate significant extravascular lung water due to increased capillary permeability.

FACTT Trial

The Fluid and Catheter Treatment Trial (FACTT) compared a conservative fluid strategy (targeting a lower CVP/PAOP using diuretics and fluid restriction) to a liberal strategy. The conservative strategy resulted in a significant increase in ventilator-free days and improved lung function, without increasing the incidence of acute kidney injury or shock.

Application

Once a patient is hemodynamically stable and off vasopressors, a conservative fluid management strategy (often utilizing furosemide) should be implemented to achieve an even or net-negative fluid balance, helping to "dry out" the lungs and facilitate extubation.